Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
In its Phase I/II Brainshuttle AD study, 92% of people receiving trontinemab showed no measurable amyloid plaques after 28 weeks of treatment
This month's Broker Brief breaks down: - Why up to 65% of GLP-1 users discontinue within a year, and why that turns coverage into a sunk cost for employers - What oral GLP-1s like Lilly's Foundayo mean for demand, when most plans still have eligibility rules written for injectables only - How fast a PBM formulary decision can move, using this year's Zepbound to Wegovy switch and back as the case in point - Why 38% of employers already tie GLP-1 coverage to participation in a lifestyle or behavioral program If you're advising employers on GLP-1 coverage, this is where the conversation is heading
Get BulkSupplements.com L-Carnitine HCl Powder for enhanced energy and fat metabolism
Is It Possible To Stop Using GLP-1 Medications
The reduced caloric intake means every calorie carries more nutritional weight
Ozempic Eligibility: For use by those who have type 2 diabetes and require controlling their blood sugar levels
